Analysis of the consumption of H2-receptor antagonists in Ukraine and European countries

Authors

DOI:

https://doi.org/10.24959/cphj.18.1462

Keywords:

H2-receptor antagonists, assortment of drugs, pharmaceutical market, ATC / DDD methodology, consumption of drugs

Abstract

H2-receptor antagonists are one of the main antisecretory drugs and have certain advantages in the treatment of the acid related diseases.

Aim. To assess the consumption of H2-receptor antagonists in Ukraine and European countries in 2015-2017.

Materials and methods. Data from the “Pharmexplorer” information system by Morion company were used to analyze the assortment and the consumption volumes of H2-receptor antagonists in Ukraine. The assessment of the volume, structure and dynamics of the drug consumption of this group in Ukraine was conducted based on the number of the defined daily doses (DDD) of drugs consumed using the ATC / DDD methodology, as well as by the number of the drug packs sold. The level of the drug consumption of H2-receptor antagonists by the indicator “DDDs/1000 inhabitants/day” in the countries of Europe was determined by the statistical data of these countries.

Results. In 2015-2017, H2-receptor antagonists were presented in Ukraine in the number of 2 international non-patented names, 26-29 trade names (TN), and they had rather wide range of prices pre a pack. The tendency to decrease in the number of their TN was observed from 2015 to 2017. The consumption of H2-receptor antagonists by the number of the packs sold and the number of DDDs consumed increased in Ukraine over the period under study. Ranitidine took leading positions by these indicators of consumption. Ukraine was ranked second among the European countries (Norway, Lithuania, Latvia, Estonia) by the level of consumption of H2-receptor antagonists by the indicator “DDDs/1000 inhabitants/day”. Ranitidine was the leader in consumption in all countries studied.

Conclusions. The consumption volume of H2-receptor antagonists by the number of the packs sold and the number of DDDs consumed increased in Ukraine in 2015-2017. The level of the drug consumption of this group by the indicator “DDDs / 1000 inhabitants / day” in Ukraine in 2015-2017 did not correspond to the level of consumption of H2-receptor antagonists in European countries.

Author Biographies

O. O. Gerasymova, National University of Pharmacy

Candidate of Pharmacy (Ph.D.), associate professor of the Department of Pharmacoeconomics

L. V. Iakovlieva, National University of Pharmacy

Doctor of Pharmacy (Dr. habil.), professor, head of the Department of Pharmacoeconomics

M. M. Udovichenko, National University of Pharmacy

student of the specialty “Clinical Pharmacy”

S. S. Shershnova, National University of Pharmacy

student of the specialty “Clinical Pharmacy”

References

Tkach, S. M., Dorofeev, A. E. (2015). Hastroenterolohiia, 4 (58), 94–100.

Vasilev, Yu. V. (2011). Mezhdunarodnyi meditcinskii zhurnal, 4, 36–40.

Nikushkina, I. N, Lezhneva, Yu. A., Shakh, Yu. S. (2014). Meditcinskii sovet, 17, 38–41.

Zhuravleva, L. V., Tcivenko, O. I., Lakhno, O. V. (2012). Liky Ukrainy, 10 (166), 75–78.

Rumiantsev, Yu. V., Osodlo, H. V., Kalashnikov, М. A. (2010). Suchasna hastroenterolohiia, 5 (55), 65–68.

Kotvitska, А. А., Khodakovska, V. P. (2014). Vestnik Tadzhikskogo natcionalnogo universiteta. Seriia estestvennykh nauk, 1/3 (134), 181–186.

Fedosov, A. I., Kyslychenko, V. S., Volkova, A. V. (2015). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 6 (44), 90–94.

Tikhonov, O. I., Bohdan, N. S., Shpychak, O. S. (2016). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 4 (48), 78–86.

Slobodianiuk, M. M., Ivchenko, A. V. (2007). Provizor, 16, 8–11.

Vishnytska, I. V. (2015). Orhanizatsiino–ekonomichne obhruntuvannia likarskoho zabezpechennia khvorykh ditei na hastryt i duodenit. Kyiv, 26.

Systema doslidzhennia rynku likarskykh zasobiv «Pharmexplorer» kompanii «Morion». Available at: www.pharmstandart.com.ua

Morozov, A. M., Yakovlieva, L. V., Stepanenko, A. V. et al. (2013). Vyvchennia spozhyvannia likarskykh zasobiv za anatomo–terapevtychno–khimichnoiu klasyfikatsiieiu ta vstanovlenymy dobovymy dozamy (ATS/DDD–metodolohiia). Kharkiv: Styl–Yzdat

Chaberda, A. E. (2017). Kachestvennaia klinicheskaia praktika, 1, 42–45.

Sammul, M., Seep, J. et al. (2017). Statistical yearbook of the state agency of medicines 2017. Tartu: State Agency of Medicines, 39.

15. Estonian Statistics on Medicines 2017. Available at: https://www.ravimiamet.ee/sites/default/files/ddd_2017_eng.pdf

Sakshaug, S. et al. (2018). Legemiddelforbruket i Norge 2013–2017. Legemiddelstatistikk 2018:1 [Drug Consumption in Norway 2013–2017. Drug Statistics 2018: 1].Oslo: Folkehelseinstituttet, 100.

Statistics on medicines consumption 2017. (2018). Riga: State Agency of Medicines, 70.

Ataskaita apie 2017 metais suvartotus vaistus. Available at: http://www.vvkt.lt/index.php?4130823002

Published

2018-06-05

Issue

Section

Pharmacoeconomics